Steven Levine, MD

Explore the ethical dilemmas of vaccine policy and public trust in health systems as experts discuss the impact of COVID-19 on immunization attitudes.

This episode unpacks ethical challenges of psychedelic therapies, such as consent and integrating traditional practices into mainstream medicine.

In part 2 of this 2-part discussion, hosts discuss ethical considerations and the growing evidence base around euthanasia and medical assistance in dying.

In part 1 of this 2-part discussion, hosts explore the ethical foundation and background of euthanasia and medically-assisted suicide.

An expert panel shares insight on the future treatment landscape for treatment-resistant depression.

Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in treatment-resistant depression, as well as alternative payment models.

Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for treatment-resistant depression.

Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for treatment-resistant depression along with implications to patients.

Key opinion leaders discuss navigation through challenges with appropriate coding for the treatment of patients with treatment-resistant depression.

Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.

Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD, including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies, and explain barriers within the health care system that inhibit access.

Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.

Experts in behavioral health discuss therapeutic options for TRD and considerations for defining value.

Dr Samuel Nordberg and Carrie Jardine discuss barriers to accessing care for patients with TRD and provide insight on addressing these concerns to achieve optimal care.

Dr Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.

Patricia Ares-Romero, MD, reviews the frequency of TRD diagnosis and common risk factors, and Martin Rosenzweig, MD, explores patient identification and economic burden of disease.

Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.